Luye Pharma

Corporate brand

Luye Pharma is a Chinese pharmaceutical group developing, manufacturing, and commercializing medicines, with particular strengths in central nervous system, oncology, cardiovascular and metabolic therapies.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Luye Pharma is the international operating brand of Luye Pharma Group, a Chinese pharmaceutical company headquartered in Yantai, Shandong. The group was established in 1994 and has developed from a domestic pharmaceutical manufacturer into a research-oriented company with operations and commercial activities spanning China and selected overseas markets. Its business combines internal drug discovery and development, manufacturing, licensing, acquisitions, and commercialization partnerships. The company’s principal therapeutic focus areas include central nervous system disorders, oncology, cardiovascular and metabolic diseases, and other specialist-care categories. Luye has built particular visibility through long-acting and extended-release drug-delivery technologies. These include transdermal systems, sustained-release injectable formulations, and other approaches intended to improve adherence, reduce dosing frequency, or extend the usable life of established active ingredients. This technology orientation is central to the group’s positioning: rather than competing only through conventional generics, Luye has sought to create differentiated formulations and innovative medicines that can be commercialized across multiple territories. In China, the company has operated as an integrated pharmaceutical business with research, clinical development, production, regulatory, and sales capabilities. Its portfolio has included prescription medicines in areas such as psychiatric and neurological care, oncology, cardiovascular treatment, and metabolic disease. The company has also developed or commercialized products outside China, using regulatory filings, local subsidiaries, licensing arrangements, and acquisitions to enter international markets. Luye’s central nervous system portfolio has included long-acting treatments for schizophrenia and related conditions. Rykindo, a sustained-release risperidone injection, became one of the group’s most visible international development programs and was approved in the United States in 2023 for the treatment of schizophrenia in adults and as maintenance monotherapy for bipolar I disorder in adults. The company has also pursued transdermal delivery products, including a rivastigmine patch for Alzheimer’s disease and Parkinson’s disease dementia, reflecting its interest in drug-delivery platforms as well as therapeutic areas. A major stage in the company’s expansion came with its 2014 listing in Hong Kong. The listing provided a public-market platform for research investment, manufacturing expansion, international business development, and acquisitions. Luye subsequently increased its overseas presence through transactions and partnerships, including the acquisition of AstraZeneca’s rights to Seroquel and Seroquel XR in certain markets in 2017 and the acquisition of specialized pharmaceutical businesses in Europe. These moves expanded the group’s commercial infrastructure and added established products to its portfolio while its internally developed pipeline continued to advance. The company’s business model therefore contains several layers: proprietary research and clinical development; production of finished pharmaceutical products; commercialization of internally developed and licensed medicines; and strategic acquisitions. Its long-term challenge is typical of internationally expanding pharmaceutical companies: it must translate promising research into approvals and recurring sales while managing clinical, regulatory, manufacturing, reimbursement, intellectual-property, and market-access risks in several jurisdictions. Luye Pharma remains an active pharmaceutical group rather than a consumer-facing healthcare label. Its brand is most closely associated with prescription medicines, specialty therapies, formulation technology, and international expansion. Public information about exact product sales, geographic revenue contribution, and current management responsibilities should be checked against the latest annual report and regulatory filings because these details change over time.

History

Luye Pharma was established in China in 1994 under the leadership of Liu Dianbo. Its early development followed the broader growth of China’s modern pharmaceutical industry, with the company building domestic capabilities in pharmaceutical research, manufacturing, registration, and sales. Over time, Luye moved beyond a primarily domestic manufacturing model and began to emphasize innovative medicines and differentiated formulations. The group’s research strategy has placed considerable weight on drug-delivery technologies. Long-acting injections, sustained-release systems, and transdermal patches can provide clinical or practical advantages over immediate-release formulations, including less frequent dosing and potentially improved adherence. Luye applied this approach across central nervous system and other specialist therapeutic areas. Its portfolio and pipeline have also covered oncology, cardiovascular disease, metabolic disorders, and additional prescription-medicine categories. The company became publicly listed on the Main Board of the Hong Kong Stock Exchange in 2014. The listing marked an important institutional transition, giving Luye access to public equity markets and greater visibility among international investors. It also supported the company’s stated ambition to strengthen research and development, expand production, and build a multinational commercial organization. International expansion subsequently became a major part of the group’s history. Luye used licensing, partnerships, subsidiaries, and acquisitions to obtain products and commercial capabilities outside mainland China. In 2017, it announced an agreement with AstraZeneca concerning rights to Seroquel and Seroquel XR in specified markets. The transaction broadened Luye’s presence in central nervous system medicines and demonstrated the company’s willingness to combine internally developed products with established licensed brands. Luye also developed a pipeline of proprietary or internally controlled products. Rykindo, a sustained-release risperidone injection, became a notable example of the group’s formulation strategy. After clinical and regulatory development, the product received United States approval in 2023 for adult schizophrenia and maintenance monotherapy for adult bipolar I disorder. The approval represented an important international regulatory milestone for Luye and provided a commercial foothold in the U.S. long-acting injectable antipsychotic market. The group has continued to operate through a combination of research and development, manufacturing, regulatory submissions, commercial sales, licensing, and business development. Its international structure has included operations or commercial activity in China, North America, Europe, and other markets, although the exact footprint and product availability vary by country. Products may be sold under different brand names, through local partners, or under rights that are limited to particular territories. Luye’s history is consequently characterized by a shift from a Chinese pharmaceutical enterprise toward a more globally integrated specialty-drug company. Its principal strategic themes have been formulation innovation, therapeutic specialization, portfolio expansion, and internationalization. The company’s future development depends on the clinical success of its pipeline, regulatory approvals, reimbursement and market access, manufacturing execution, protection of intellectual property, and the performance of products obtained through licensing or acquisition.

2023
Rykindo approved in the United States
[3]U.S. Food and Drug Administration: approval of long-acting injectable risperidonefda.gov
The FDA approved Rykindo, a long-acting risperidone injection, for adult schizophrenia and maintenance monotherapy for adult bipolar I disorder.
2017
Acquisition of selected Seroquel rights
[1]Luye Life Sciences Group official website homepageluye.com
Luye announced an agreement with AstraZeneca to acquire Seroquel and Seroquel XR commercialization rights in specified markets.
2014
Hong Kong stock-market listing
[2]Hong Kong Exchanges and Clearinghkex.com.hk
Luye Pharma Group listed on the Main Board of the Hong Kong Stock Exchange under stock code 2186.
1994
Company established
[1]Luye Life Sciences Group official website homepageluye.com
Luye Pharma was established in China and began building pharmaceutical research, manufacturing, and commercial capabilities.

Products and positioning

A research-oriented Chinese pharmaceutical group positioned around differentiated formulations, long-acting drug delivery, specialty prescription medicines, and international commercialization.

Long-acting injectable antipsychotic · 2023
Rykindo
Rykindo is Luye Pharma’s extended-release injectable formulation of risperidone. It is administered at intervals longer than conventional immediate-release oral treatment and is designed for maintenance therapy. The product received U.S. approval in 2023 for schizophrenia in adults and maintenance monotherapy for bipolar I disorder in adults. Its development illustrates Luye’s emphasis on long-acting drug-delivery systems and central nervous system medicines.
Transdermal neurological medicine
Rivastigmine transdermal patch
Luye has developed and commercialized rivastigmine transdermal patch products for use in dementia-related treatment markets. The patch-based presentation reflects the group’s wider interest in transdermal delivery and in formulations that can provide an alternative to conventional oral dosing. Product approval, branding, and commercialization rights differ by territory.
Central nervous system medicines
Seroquel and Seroquel XR
Seroquel and Seroquel XR are quetiapine products originally developed by AstraZeneca. Luye Pharma acquired commercialization rights in specified markets through an agreement announced in 2017. They are included in Luye’s portfolio only in the territories covered by the relevant rights and should not be treated as globally owned Luye products.

Controversies

2016
Source

2023
United States launch pathway for RykindoProduct launch
Background
Luye pursued international regulatory approval for a long-acting risperidone formulation as part of its differentiated drug-delivery strategy.
Action taken
The U.S. Food and Drug Administration approved Rykindo for adult schizophrenia and maintenance monotherapy for adult bipolar I disorder.
Aftermath
The approval created an opportunity for Luye to commercialize an internally developed long-acting central nervous system product in the United States.
Source
2017
Acquisition of selected Seroquel commercialization rightsM&A
Background
Luye sought to strengthen its international central nervous system portfolio with established prescription products.
Action taken
The company entered an agreement with AstraZeneca for Seroquel and Seroquel XR rights in specified markets.
Aftermath
The transaction expanded Luye’s commercial presence in central nervous system medicines, although the rights were geographically limited.
Source
2014
Public listing to support expansionStrategy
Background
Luye was developing from a domestic pharmaceutical business into a research-led company with ambitions in international markets.
Action taken
Luye Pharma Group listed on the Hong Kong Stock Exchange, giving the group access to public capital markets and a broader investor base.
Aftermath
The listing became a foundation for subsequent research investment, portfolio development, international transactions, and commercial expansion.
Source

Recent events

2021-09-30
China approves LY03015 clinical trial[9]LY03015获准在中国开展临床试验prnasia.com
Reported: 2021-09-29
China's Center for Drug Evaluation approved Green Valley Pharmaceutical's investigational drug LY03015 for clinical trials.
2020-03-27
Luye Pharma releases 2019 annual results[10]绿叶制药发布2019年全年业绩prnasia.com
Reported: 2020-03-27
Luye Pharma Group released its 2019 annual results, reporting sales revenue of RMB 6.358 billion, up 22.9% year over year.
2019-12-01
GreenLeaf Pharmaceutical announced acquisition of Boan Biotech[11]绿叶制药宣布收购博安生物finance.sina.com.cn
Reported: 2019-12-03
GreenLeaf Pharmaceutical announced that it would acquire Shandong Boan Biotechnology Co., with the transaction priced at 1.447 billion yuan and paid in installments under the agreement.
2019-12-01
Luye Pharma announces acquisition of Boan Biotech[12]绿叶制药宣布收购博安生物prnasia.com
Reported: 2019-12-01
Luye Pharma announced that it would acquire Shandong Boan Biotechnology, including Boan's products under development, antibody-screening platform, intellectual property and antibody-production platform. The transaction was to be paid in installments.
2019-12-01
Green Leaf announces acquisition of 98% of Shandong Boan[13]绿叶制药宣布收购山东博安98%股权finance.sina.com.cn
Reported: 2019-12-01
Green Leaf Pharmaceutical announced that its wholly owned subsidiary would acquire a 98% stake in Shandong Boan Biotechnology from Green Leaf Investment Group for a total purchase price of up to RMB 1.4467 billion.

Sources15 sources

Cite this profile: Cite the canonical profile. /brand-wiki/绿叶制药 · Editorial policy · How profiles are compiled